A Phase Ib Open-label, Randomized Trial Evaluating Neoadjuvant Ateganosine and Cadonilimab in Resectable Hepatocellular Carcinoma
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Cadonilimab (Primary) ; Ateganosine
- Indications Liver cancer
- Focus Adverse reactions
Most Recent Events
- 06 Mar 2026 New trial record